home / stock / apvo / apvo news


APVO News and Press, Aptevo Therapeutics Inc. From 11/14/23

Stock Information

Company Name: Aptevo Therapeutics Inc.
Stock Symbol: APVO
Market: NASDAQ
Website: aptevotherapeutics.com

Menu

APVO APVO Quote APVO Short APVO News APVO Articles APVO Message Board
Get APVO Alerts

News, Short Squeeze, Breakout and More Instantly...

APVO - Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

The Company's ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Continues to Progress Planning for APVO436 Phase 2 Trial Initiation in Both Relapsed/Refractory and Frontline AML Ongoing Extended Cash Runway with $7 Million in Funding and Potential for Additional $9....

APVO - Expected US Company Earnings on Thursday, November 9th, 2023

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

APVO - Expected earnings - Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. (APVO) is expected to report $-0.72 for Q3 2023

APVO - Aptevo to Present at Bio-Europe Conference

SEATTLE, WA / ACCESSWIRE / November 1, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced that the ...

APVO - Aptevo Therapeutics GAAP EPS of -$1.23 misses by $0.11

2023-08-10 10:53:11 ET Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of -$1.23 misses by $0.11 . Aptevo had cash and cash equivalents as of June 30, 2023 totaling $21.0 million (exclusive of the proceeds from the equity raised closed on August 4, 2023...

APVO - Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AML APVO436 Poised for Phase 2 Trial Initiation Later in 2H23 Company Completes $5 million Equity Raise, Extending Cash Runway into 3Q24 SEATTLE, WA / ACCESSWIRE / A...

APVO - Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

SEATTLE, WA / ACCESSWIRE / August 4, 2023 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical stage biotechnology company focused on developing novel immuno-oncology therapeutics, today announced the closing of its previously announced public offering of 2,221,550 sh...

APVO - Is AMD Stock the Next Big AI Play?

2023-08-02 09:48:19 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Advanced Micro Devices (NASDAQ: AMD ) stock is in the news Wednesday as investors wonder if the tech company can succeed in the artificial intelligence ( AI ) market. AM...

APVO - MTCH Stock Price Prediction: Can Match Group Rally 30% From Here?

2023-08-02 09:26:24 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Match Group (NASDAQ: MTCH ) stock is on the move Wednesday after getting a new price prediction from BTIG analyst Jake Fuller. According to the analysts, shares of MTCH ...

APVO - Why Is Aptevo Therapeutics (APVO) Stock Down 33% Today?

2023-08-02 08:58:27 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aptevo Therapeutics (NASDAQ: APVO ) stock is sliding lower on Wednesday after the biotechnology company announced a public share offering . The APVO stock offering has t...

Previous 10 Next 10